TY - JOUR
T1 - Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies
T2 - A European Case Series
AU - Rau, Cornelius
AU - Auer-Hackenberg, Lorenz
AU - Deubzer, Hedwig E
AU - Schwabel, Elisabeth
AU - Jaros, Maria
AU - Diederichs, Antonia
AU - Lehrnbecher, Thomas
AU - Holm, Mette
AU - von Linstow, Marie-Louise
AU - Martin, Luise
AU - Dinges, Sarah Svenja
AU - Rothensteiner, Maria
AU - Siepermann, Meinolf
AU - Strenger, Volker
AU - von Both, Ulrich
AU - Teig, Norbert
AU - Brinkmann, Folke
AU - Leeb, Franziska
AU - Zeitlinger, Markus
AU - Kobbe, Robin
AU - Götzinger, Florian
N1 - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - BACKGROUND: Although severe COVID-19 in children is rare, those with certain pre-existing health conditions are more prone to severe disease. Monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are potent antiviral agents that reduce adverse clinical outcomes in adults, but are commonly not approved for use in pediatric patients.METHODS: We retrospectively evaluated mAb treatment in children <12 years of age or <40kg with SARS-CoV-2 infection between January 1, 2021, and March 7, 2022, in 12 tertiary care centers in 3 European countries.RESULTS: We received data from 53 patients from Austria, Denmark and Germany. Median age was 5.4 years [0-13.8, interquartile range (IQR) = 6.2], and median body weight was 20 kg (3-50.1, IQR = 13). The most frequent SARS-CoV-2 variant in this study, if known, was Omicron, followed by Delta and Alpha. Pre-existing conditions included immunodeficiency, malignancy, hematologic disease, cardiac disease, chronic lung disease, chronic liver disease, kidney disease and diabetes. Forty-two patients received sotrovimab (79%), 9 casirivimab/imdevimab (17%) and 2 bamlanivimab (4%). All but 1 patient survived. Median duration of hospital stay was 3 days (0-56, IQR = 6). Seven patients required treatment in an intensive care unit, and 5 required high-flow nasal cannula treatment. Potential side effects included neutropenia (6/53, 11%), lymphopenia (3/53, 6%), nausea or vomiting (2/53, 4%), rise of alanine transaminase (1/53, 2%) and hypotonia (1/53, 2%).CONCLUSIONS: MAb treatment was well tolerated by children in this cohort.
AB - BACKGROUND: Although severe COVID-19 in children is rare, those with certain pre-existing health conditions are more prone to severe disease. Monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are potent antiviral agents that reduce adverse clinical outcomes in adults, but are commonly not approved for use in pediatric patients.METHODS: We retrospectively evaluated mAb treatment in children <12 years of age or <40kg with SARS-CoV-2 infection between January 1, 2021, and March 7, 2022, in 12 tertiary care centers in 3 European countries.RESULTS: We received data from 53 patients from Austria, Denmark and Germany. Median age was 5.4 years [0-13.8, interquartile range (IQR) = 6.2], and median body weight was 20 kg (3-50.1, IQR = 13). The most frequent SARS-CoV-2 variant in this study, if known, was Omicron, followed by Delta and Alpha. Pre-existing conditions included immunodeficiency, malignancy, hematologic disease, cardiac disease, chronic lung disease, chronic liver disease, kidney disease and diabetes. Forty-two patients received sotrovimab (79%), 9 casirivimab/imdevimab (17%) and 2 bamlanivimab (4%). All but 1 patient survived. Median duration of hospital stay was 3 days (0-56, IQR = 6). Seven patients required treatment in an intensive care unit, and 5 required high-flow nasal cannula treatment. Potential side effects included neutropenia (6/53, 11%), lymphopenia (3/53, 6%), nausea or vomiting (2/53, 4%), rise of alanine transaminase (1/53, 2%) and hypotonia (1/53, 2%).CONCLUSIONS: MAb treatment was well tolerated by children in this cohort.
UR - http://www.scopus.com/inward/record.url?scp=85146365172&partnerID=8YFLogxK
U2 - 10.1097/INF.0000000000003773
DO - 10.1097/INF.0000000000003773
M3 - Journal article
C2 - 36638398
SN - 0891-3668
VL - 42
SP - 125
EP - 129
JO - The Pediatric infectious disease journal
JF - The Pediatric infectious disease journal
IS - 2
ER -